EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown

Anna Pendrey iD, Javier Sevilla-Martir

Obesity · 2025-11 · 33 (S1) · 57-73

DOI: 10.1002/oby.70029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Obesity, online erschienen am 08.10.2025. Verfasst von Anna Pendrey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Obesity affects 42% of older adults, with rates continuing to rise. This a complex condition influenced by non‐modifiable as well as modifiable risk factors. The disease can be treated through modifications to diet, physical activity, and behavior and more recently through antiobesity medications (AOMs) and surgery. Treatment must be tailored to individual needs due to age‐related metabolic and physiological changes. This review aimed to identify the suitability of seven FDA‐approved AOMs in the treatment of obesity in older adults.

Methods

A review of AOMs was performed, focusing on their efficacy in weight loss, side effects, and potential health risks in older adults. Studies were selected to later evaluate the overall suitability and safety of these medications.

Results

AOMs can improve cardiovascular outcomes, hypertension, hyperlipidemia, metabolic liver disease, obstructive sleep apnea, and chronic kidney disease. Weight loss in older adults using AOMs is associated with an increased risk of sarcopenia.

Conclusions

From a policy standpoint, ensuring coverage of AOMs for older adults is critical, as these medications help reduce obesity‐related complications. However, increased participation in clinical trials is urgently needed to study the impact of quality of life and outcomes in older adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityHumansAgedWeight LossCardiovascular DiseasesHypertensionSarcopeniaHyperlipidemiasRisk FactorsSleep Apnea, Obstructive

Stichwörter der Autor:innen

antiobesity medicationsobesityolder adults

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Anna Pendrey

Zitieren

APA

Pendrey, A., & Sevilla-Martir, J. (2025). Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown. Obesity, 33(S1), 57-73. https://doi.org/10.1002/oby.70029

Vancouver

Pendrey A, Sevilla-Martir J. Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown. Obesity. 2025;33(S1):57-73. doi:10.1002/oby.70029

BibTeX
@article{Pendrey2025,
  author = {Pendrey, Anna and Sevilla-Martir, Javier},
  title = {Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {S1},
  pages = {57--73},
  doi = {10.1002/oby.70029}
}
Kostenlos starten →